R Simó, A Lecube, L Sararols, J García- … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—SLI in the vitreous fluid was significantly lower in diabetic patients
than in the control group (68 ± 18.7 vs. 193.6 ± 30.8 pg/ml, P < 0.01). The
vitreous SLI-to-plasma SLI ratio was strikingly higher in nondiabetic ... Cited by 18 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org C Hernández, E Carrasco, R Casamitjana, R … - Diabetes Care, 2005 - Am Diabetes Assoc OBJECTIVE—There is growing evidence to indicate that somatostatin could be
added to the list of natural antiangiogenic factors that exist in the vitreous
fluid. In addition, a deficit of intravitreous somatostatin-like ... Cited by 22 - Related articles - BL Direct - All 5 versions
R Simó, E Carrasco, A Fonollosa, J García- … - Diabetes care, 2007 - Am Diabetes Assoc Although diabetic macular edema (DME) is the main cause of visual loss in type 2
diabetic patients (1), its pathogenic mechanisms have been much less studied
than proliferative diabetic retinopathy (PDR). The production of both ... Cited by 9 - Related articles - BL Direct - All 5 versions
MI Davis, SH Wilson, MB Grant… - Hormone and Metabolic Research, 2001 - thieme-connect.com Clinical management of proliferative diabetic retinopathy has changed very
little in the last 5 decades, relying primarily on laser ablation of the retinal
vasculature. Several lines of clinical and experimental evidence suggest ... Cited by 26 - Related articles - BL Direct - All 4 versions
PM Van Hagen, GS Baarsma, CM Mooy, EM … - EUROPEAN JOURNAL OF ENDOCRINOLOGY- …, 2000 - EFES Introduction Somatostatin is a small neuropeptide that is produced in the
central nervous system, where it acts as a neurotransmitter. This neuropeptide
also has an important role in the neuroendocrine system as an inhibitor of ... Cited by 39 - Related articles - BL Direct - All 13 versions
- ►endocrinology-journals.org [PDF] A Baldysiak-Figiel, GK Lang, J Kampmeier, … - Journal of Endocrinology, 2004 - Soc Endocrinology Ocular diseases such as proliferative diabetic retinopathy are the major cause
of blindness in industrialized countries. The main pathologic features of these
diseases are hypoxia and overproduction of growth factors resulting in ... Cited by 22 - Related articles - BL Direct - All 6 versions
C Hernández, R Simó - Expert Opinion in Investigational Drugs, 2007 - informahealthcare.com Proliferative diabetic retinopathy (PDR) demands both more effective and less
expensive biologically based treatments. Our understanding of the
pathophysiology of the disease is increasing as new biochemical pathways ... Cited by 9 - Related articles - BL Direct - All 5 versions
JW Sall, DD Klisovic, MS O'Dorisio, SE Katz - Experimental eye research, 2004 - Elsevier Neovascularization stimulated by IGF-1 mediated induction of vascular
endothelial growth factor (VEGF) is one of the leading causes of blindness in
humans. It plays a central role in the pathogenesis of proliferative ... Cited by 32 - Related articles - All 3 versions
I Kurnatowska, M Pawlikowski - Neuroimmunomodulation, 2000 - content.karger.com The aim of the present study was the estimation of the anti-inflammatory effects
of the somatostatin analogs, octreotide (OCT) and vapreotide (RC-160), in
zymosan-induced mice ear inflammation and to compare their effects with ... Cited by 7 - Related articles - BL Direct - All 4 versions
R Simo, E Carrasco, M Garcia-Ramirez, C … - Current Diabetes Reviews, 2006 - ingentaconnect.com Abstract: Diabetic retinopathy continues to be the leading cause of legal
blindness among working-age individuals. The earliest histological features of
diabetic retinopathy include neuroretinal damage, capillary basement ... Cited by 34 - Related articles - BL Direct - All 2 versions
